THINQ Pharma CRO Ltd.   Report issue

For profit Phase 3
Founded: Mumbai India (1989)

Organization Overview

First Clinical Trial
2016
NCT02635438
First Marketed Drug
2005
fluconazole (diflucan)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Thinq Pharma-CRO Pte. Ltd. | THINQ PHARM-CRO PVT

Active Ingredients

Marketed Drugs (2)

fluconazole (diflucan) (2005)

ranitidine (zantac) (2019)

Drugs in Phase 3 Trials (1)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Candidiasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1